These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 8252509

  • 21. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin.
    Falkson CI, Falkson G, Falkson HC.
    Ann Oncol; 1991 Apr; 2(4):303-4. PubMed ID: 1907843
    [Abstract] [Full Text] [Related]

  • 22. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
    Waxman J.
    Prog Clin Biol Res; 1989 Apr; 303():61-8. PubMed ID: 2528741
    [No Abstract] [Full Text] [Related]

  • 23. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
    Iversen P, Christensen MG, Friis E, Hornbøl P, Hvidt V, Iversen HG, Klarskov P, Krarup T, Lund F, Mogensen P.
    Cancer; 1990 Sep 01; 66(5 Suppl):1058-66. PubMed ID: 2144207
    [Abstract] [Full Text] [Related]

  • 24. [Treatment of advanced cancer of the prostate using LHRH analogs. How can a possible initial flare-up be prevented?].
    Bouffioux C, Denis L, Mahler C, de Leval J.
    Acta Urol Belg; 1986 Sep 01; 54(3):304-8. PubMed ID: 2946208
    [No Abstract] [Full Text] [Related]

  • 25. Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.
    Migliari R, Scarpa RM, Campus G, De Lisa A, Zucca I, D'Atri M, Serra A, Usai E.
    Arch Ital Urol Nefrol Androl; 1991 Mar 01; 63(1):147-53. PubMed ID: 1830407
    [Abstract] [Full Text] [Related]

  • 26. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM.
    Am J Clin Oncol; 1988 Mar 01; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [Abstract] [Full Text] [Related]

  • 27. Buserelin as primary therapy in advanced prostatic carcinoma.
    Presant CA, Soloway MS, Klioze SS, Kosola JW, Yakabow AL, Mendez RG, Kennedy PS, Wyres MR, Naessig VL, Ford KS.
    Cancer; 1985 Nov 15; 56(10):2416-9. PubMed ID: 3930064
    [Abstract] [Full Text] [Related]

  • 28. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
    Wenderoth UK, Jacobi GH.
    Ann Urol (Paris); 1986 Nov 15; 20(2):95-7. PubMed ID: 3087269
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Treatment of advanced prostatic cancer with buserelin, an analogue of gonadotrophin releasing hormone.
    Waxman JH, Wass JA, Hendry WF, Whitfield HN, Bary P, Besser GM, Malpas JS, Oliver RT.
    Br J Urol; 1983 Dec 15; 55(6):737-42. PubMed ID: 6418264
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Intranasal buserelin in the treatment of advanced prostatic cancer: a phase II trial.
    Falkson G, Vorobiof DA.
    J Clin Oncol; 1987 Sep 15; 5(9):1419-23. PubMed ID: 3114438
    [Abstract] [Full Text] [Related]

  • 33. Androgens do not regulate the growth hormone response to GHRH in elderly men.
    Ceda GP, Ceresini G, Denti L, Cortellini P, Hoffman AR, Valenti G.
    Horm Metab Res; 1989 Dec 15; 21(12):695-6. PubMed ID: 2533140
    [No Abstract] [Full Text] [Related]

  • 34. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N, Takizawa I, Isahaya E, Nishiyama T, Hoshii T, Ishizaki F, Takahashi K.
    Urol Oncol; 2012 Sep 15; 30(5):596-601. PubMed ID: 21458314
    [Abstract] [Full Text] [Related]

  • 35. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
    Niijima T, Kishimoto T, Shimazaki J, Yoshida O, Isurugi K.
    Hinyokika Kiyo; 1988 Jul 15; 34(7):1309-19. PubMed ID: 3140622
    [Abstract] [Full Text] [Related]

  • 36. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K, Lehnert M, Stettner H, Hubmer G.
    Eur Urol; 1997 Jul 15; 32 Suppl 3():81-5. PubMed ID: 9267791
    [Abstract] [Full Text] [Related]

  • 37. EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
    Robinson MR, Denis L, Newling DW, Sylvester R, De Pauw M.
    Cancer; 1990 Sep 01; 66(5 Suppl):1022-4. PubMed ID: 2144204
    [Abstract] [Full Text] [Related]

  • 38. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM, Dahan R.
    N Engl J Med; 1989 Aug 17; 321(7):413-8. PubMed ID: 2503723
    [Abstract] [Full Text] [Related]

  • 39. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V, al-Abadi H, Nagel R.
    Am J Clin Oncol; 1988 Aug 17; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [Abstract] [Full Text] [Related]

  • 40. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects.
    Fleshner NE, Trachtenberg J.
    J Urol; 1995 Nov 17; 154(5):1642-5; discussion 1645-6. PubMed ID: 7563310
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.